Cartesian Therapeutics Reports Q2 Results, Cash Runway Into 2028, and Four Clinical Readouts in Next 12 Months
RNAC sits 48% above its 52-week low of $5.6.
Summary
Cartesian reported Q2 2026 financials with $149.3M in cash as of June 30, enough to fund operations into 2028. The company reiterated timelines for four key clinical readouts over the next year: Phase 3 AURORA data in myasthenia gravis (1Q27), Phase 2 TRITON data in myositis (1H27), Phase 1/2 HELIOS pediatric data (1H27), and initial in vivo CAR-T data from the WestGene partnership (1H27). The WestGene Phase 1 trial is set to start in 2H26. This follows the $50M non-dilutive credit facility secured in May and the WestGene licensing deal announced in June. The extended cash runway reduces near-term dilution risk, but the stock's reaction will hinge on whether the market views the reiterated timelines as credible given the early-stage nature of the pipeline.
At the time of this announcement, RNAC was trading at $8.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $245.3M. The 52-week trading range was $5.60 to $12.57. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.